BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26496271)

  • 1. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
    Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
    BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective evaluation of the clinical utility of serological biomarkers in Chinese patients with inflammatory bowel disease: 2-year clinical experience.
    Zhang S; Luo J; Li J; Wu Z; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Clin Chem Lab Med; 2017 May; 55(6):865-875. PubMed ID: 27831916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.
    Duman AE; Hülagü S; Çelebi A; Korkmaz U; Musul MM; Şentürk Ö; Şirin G; Yılmaz H; Koç DÖ; Dindar G; Öztürkler M; Bozkurt N; Kır HM
    Turk J Gastroenterol; 2019 Jan; 30(1):21-27. PubMed ID: 30465525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
    Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
    J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients.
    Lawrance IC; Murray K; Hall A; Sung JJ; Leong R
    Am J Gastroenterol; 2004 Nov; 99(11):2186-94. PubMed ID: 15555001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD.
    Lawrance IC; Hall A; Leong R; Pearce C; Murray K
    Inflamm Bowel Dis; 2005 Oct; 11(10):890-7. PubMed ID: 16189418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.
    Shpoliansky M; Roggenbuck D; Pinsker M; Salamon N; Weiss B; Shouval DS; Werner L
    Dig Dis Sci; 2021 Aug; 66(8):2619-2626. PubMed ID: 32886311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
    Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
    Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
    Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
    Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
    PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.
    Zhang S; Luo J; Wu Z; Roggenbuck D; Schierack P; Reinhold D; Li J; Zeng X; Zhang F; Qian J; Li Y
    Clin Transl Gastroenterol; 2018 Feb; 9(2):e133. PubMed ID: 29446764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic value of different serological markers and correlation analysis with disease phenotype in inflammatory bowel disease].
    Tang H; Tan B; Shen BB; Zhang SL; Qian JM
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3743-3748. PubMed ID: 36517423
    [No Abstract]   [Full Text] [Related]  

  • 19. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
    Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease.
    Nisihara RM; de Carvalho WB; Utiyama SR; Amarante H; Baptista ML
    Dig Dis Sci; 2010 Aug; 55(8):2309-15. PubMed ID: 19826949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.